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Perfluorooctanesulfonate (PFOS) and per-
ﬂuorooctanoate (PFOA) are persistent organic
pollutants (POPs), which are produced syn-
thetically or from the metabolism of other
perfluorinated chemicals (PFCs) [Butenhoff
et al. 2006; U.S. Environmental Protection
Agency (EPA) 2006]. These compounds are
widely used as industrial surfactants and emul-
sifiers and in numerous consumer products.
Nonstick pans, carpets, furniture, household
cleaners, shampoos, shoes, clothing, and con-
venience food packaging are some of the
products that can contain PFCs (Butenhoff
et al. 2006; U.S. EPA 2006).
PFOA and PFOS are slowly metabolized
and have half-lives in humans of around
4 years and 5 years, respectively (Olsen et al.
2007). They are absorbed through oral intake
or inhaled and, to a lesser extent, through der-
mal exposure. They have been detected in the
sera of occupationally and nonoccupationally
exposed human populations in various coun-
tries (Calafat et al. 2007; Kannan et al. 2004;
Karrman et al. 2006; Olsen et al. 2003; Yeung
et al. 2006), including pregnant women and
their newborn babies (Apelberg et al. 2007a;
Inoue et al. 2004; Jin et al. 2004; Karrman
et al. 2007; Midasch et al. 2007; So et al.
2006; Tittlemier et al. 2004).
Exposure of rodent dams during preg-
nancy to both PFOS and PFOA has been
associated with decrements in birth weight and
length of gestation at birth (Butenhoff et al.
2004b; Case et al. 2001; Grasty et al. 2003;
Lau et al. 2004, 2006; Luebker et al. 2005a,
2005b; Thibodeaux et al. 2003; Wolf et al.
2007). Although it is unknown how PFOS
and PFOA may impair fetal growth, several
mechanisms have been suggested, including a
disturbance of lipid metabolism (Kennedy
et al. 2004; Luebker et al. 2005b), a reduction
of food and water intake, or altered hormones
levels (Betts 2007; Lau et al. 2004; Luebker
et al. 2005b; Thibodeaux et al. 2003), but a
direct fetotoxic effect has also been suggested
(Betts 2007; Henderson and Smith 2007;
Hinderliter et al. 2005; Luebker et al. 2005a,
2005b). No effect of PFOS exposure on fetal
growth in humans was found in a study based
on self-reports of birth weight and occupa-
tional histories (Grice et al. 2007) or in a study
of maternal and cord blood samples from
15 children (Inoue et al. 2004). However, a
recent study reported levels of both PFOS
and PFOA to be inversely associated with
birth weight, newborn head circumference,
crown–heel length, and ponderal index, but
the study was based on cord blood samples
taken after delivery (Apelberg et al. 2007b).
No large-scale study based on prospectively
collected biomarkers at the time of fetal
growth has been published to date.
In this study we examined the relation
between maternal plasma PFOS and PFOA
levels during pregnancy and birth weight as
well as length of gestation using data from
the Danish National Birth Cohort (Olsen
et al. 2001).
Methods
Study population. The Danish National Birth
Cohort (DNBC) includes data on 91,827
pregnant women from March 1996 to
November 2002 (Olsen et al. 2001). Women
were recruited nationwide (a population of
5.4 million people) by their general practition-
ers (GPs) early in pregnancy. About half of all
GPs in the country participated, and about
60% of the pregnant women accepted the
invitation to participate. After providing writ-
ten informed consent, women took part in
four computer-assisted telephone interviews at
approximately 12 and 30 weeks of gestation,
and at approximately 6 and 18 months after
birth. A food frequency questionnaire was
ﬁlled out at home approximately at gestational
week 25. Moreover, blood was drawn twice
from the women, once in the ﬁrst and once in
the second trimester. An umbilical cord blood
sample was obtained shortly after birth. Each
blood sample was sent by ordinary mail to the
State Serum Institute in Copenhagen,
Denmark, and then separated and stored in
freezers at –20°C or in liquid nitrogen. Blood
samples were thus transported at outside tem-
peratures for 4–48 hr, but most of the samples
arrived within 28 hr.
Among all participants who gave birth to
a single live-born child without a reported
congenital malformation (n = 87,752), who
provided the ﬁrst blood sample between ges-
tational weeks 4 and 14 (n = 80,678), and
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BACKGROUND: Perﬂuorooctanesulfonate (PFOS) and perﬂuorooctanoate (PFOA) are man-made,
persistent organic pollutants widely spread throughout the environment and human populations.
They have been found to interfere with fetal growth in some animal models, but whether a similar
effect is seen in humans is uncertain.
OBJECTIVES: We investigated the association between plasma levels of PFOS and PFOA in preg-
nant women and their infants’ birth weight and length of gestation.
METHODS: We randomly selected 1,400 women and their infants from the Danish National Birth
Cohort among those who completed all four computer-assisted telephone interviews, provided the
ﬁrst blood samples between gestational weeks 4 and 14, and who gave birth to a single live-born
child without congenital malformation. PFOS and PFOA were measured by high performance liq-
uid chromatography–tandem mass spectrometer.
RESULTS: PFOS and PFOA levels in maternal plasma were on average 35.3 and 5.6 ng/mL, respec-
tively. Only PFOA levels were inversely associated with birth weight (adjusted β = –10.63 g; 95%
confidence interval, –20.79 to –0.47 g). Neither maternal PFOS nor PFOA levels were consis-
tently associated with the risk for preterm birth or low birth weight. We observed no adverse
effects for maternal PFOS or PFOA levels on small for gestational age.
CONCLUSION: Our nationwide cohort data suggest an inverse association between maternal plasma
PFOA levels and birth weight. Because of widespread exposure to these chemicals, our findings
may be of potential public health concern.
KEY WORDS: birth weight, cord blood, length of gestation, low birth weight, maternal blood,
PFOA, PFOS, preterm birth, small for gestational age. Environ Health Perspect 115:1677–1682
(2007). doi:10.1289/ehp.10506 available via http://dx.doi.org/ [Online 16 August 2007]who had responded to all four telephone
interviews (n = 43,045), we randomly selected
1,400 mothers. Of the 1,400 selected, 1,102
had a second blood sample, and 200 were
randomly selected among these. Of these 200,
146 had a cord blood sample from the child,
and 50 were randomly selected among these.
We used the second maternal and cord blood
samples to examine whether PFOS and
PFOA levels were stable during pregnancy
and whether the mother–offspring correlation
in blood levels was high. Sample sizes were
determined in large part by the capacity of the
laboratory to perform PFOS and PFOA
assays and by what would be acceptable for
the Steering Committee that gives permission
for use of cohort data.
Information on potential confounders—
such as infant sex, maternal age, parity, socio-
occupational status, prepregnancy body mass
index (BMI), and smoking during the preg-
nancy—was collected by highly structured
questionnaires (available at http://www.
bsmb.dk) (Olsen et al. 2001). Socio-
occupational status was based on education
and current job titles. Women with a higher
education (4 years beyond secondary school
education) or in management level jobs were
classiﬁed as “high” social status; women with
middle-range training and skilled workers were
classified as “middle”; and unskilled workers
and unemployed were classiﬁed as “low.” Birth
weight and gestational age at birth were
obtained from the National Hospital
Discharge Register at the National Board of
Health in Denmark. The assessment of gesta-
tional age was done by the midwives based on
either the ﬁrst day of the last menstrual period
(LMP) (conditioned on a regular bleeding pat-
tern during the preceding 6 months, and no
use of oral contraceptives during the 3 months
preceding pregnancy) or from ultrasound
examination done before 24 weeks of gestation
(Albertsen et al. 2004). If estimates differed,
ultrasound measures replaced the LMP esti-
mates. In most cases, gestational age was based
on early ultrasound measures. If data were
missing or out of the expected range (n = 10),
we used the expected date of delivery provided
by the pregnant women at the second inter-
view (after their ultrasound examinations).
Low birth weight (LBW) was deﬁned as birth
weight < 2,500 g. Preterm birth was deﬁned as
the birth of an infant before 37 completed
weeks of gestation (259 days), post-term birth
as after 42 completed weeks of gestation (294
days), and term birth as between 37 and 42
completed weeks of gestation. Small for gesta-
tional age (SGA) was deﬁned as an infant with
birth weight below the 10th percentile at a spe-
ciﬁc gestational age in weeks, based on all sin-
gleton live births of same sex and parity who
fulﬁlled our sampling criteria.
This research was approved by the UCLA
Office for Protection of Research Subjects
(Reference No. 06-08-023-01) and the
Danish Data Protection Agency (Reference
No. J.Nr 2006-41-6324).
Exposure assessment. We measured plasma
concentrations of PFOS and PFOA using
high performance liquid chromatography–
tandem mass spectrometry in the 3M
Toxicology Laboratory (Ehresman et al.
2007). The laboratory was blinded to birth
outcomes and types of blood drawn (first or
second maternal blood, or cord blood). Stable
labeled analogs of PFOS (18O2 PFOS) and
PFOA (13C2 PFOA) were used in all extracted
procedures. All extractions were performed
using solid phase extraction techniques and
based on 100 µL of plasma. Details of the ana-
lytical methods used are available elsewhere
(Ehresman et al. 2007).
Quality control materials, a single lot of
newborn calf serum, were analyzed together
with the samples to ensure the accuracy and
reliability of the data. Previous evaluation
comparing serum and plasma samples has
shown no significant difference when using
an extracted serum spiked standard curve
(Ehresman et al. 2007). Two levels of spiked
calf serum controls were extracted using 30
individual solid phase extractions to establish
“within”-run means and standard deviations
for each separate level of control. These levels
were calculated at 15 ng/mL and 44 ng/mL
for PFOA and 10 ng/mL and 30 ng/mL for
PFOS. A total of 35 batch runs was necessary
to complete all sample analyses. The coeffi-
cient of variations for the between-batch
spiked control values were 3.5% and 3.2%
for PFOA, respectively, and 2.8% and 2.5%
for PFOS, respectively. Blind samples were
also selected and relabeled for repeated analy-
sis. There were strong correlations between
the repeated blind analyses and the original
results for PFOS (r = 0.993, n = 100) and
PFOA (r = 0.987, n = 100). Only two PFOA
values and no PFOS values were reported at
the lower limit of quantitation (LLOQ) of
1.0 ng/mL. Values below the LLOQ (n = 2)
were assigned a value of half the LLOQ.
PFOS and PFOA measurements were deter-
mined on the residual plasma component
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Table 1. Plasma concentrations of PFOS, PFOA, and birth weight (mean ± SD) by characteristics of study
subjects (n = 1,400).
Characteristica No. (%) PFOS (ng/mL) PFOA (ng/mL) Birth weight (g)
Maternal age at delivery (years)
< 25 118 (8.4) 38.6 ± 12.0 6.2 ± 2.1 3,573 ± 492
25–29 547 (39.1) 36.8 ± 12.8 6.0 ± 2.8 3,590 ± 521
30–34 504 (36.0) 33.9 ± 13.2 5.2 ± 2.2 3,676 ± 519
≥ 35 230 (16.4) 33.0 ± 12.7 5.1 ± 2.4 3,629 ± 581
Parity
0 626 (44.7) 37.7 ± 13.0 6.6 ± 2.7 3,524 ± 514
1 508 (36.3) 33.2 ± 12.7 4.7 ± 1.9 3,689 ± 501
2 225(16.1) 34.0 ± 12.6 4.8 ± 2.3 3,723 ± 580
≥ 3 41 (2.9) 30.5 ± 11.7 3.7 ± 1.6 3,862 ± 540
Socio-occupational status
High 709 (50.8) 34.0 ± 12.7 5.6 ± 2.3 3,648 ± 527
Middle 566 (40.5) 36.6 ± 12.9 5.6 ± 2.8 3,603 ± 531
Low 121 (8.7) 36.5 ± 14.1 5.6 ± 2.3 3,606 ± 536
Prepregnancy BMI (kg/m2)
< 18.5 58 (4.2) 33.1 ± 14.3 5.2 ± 2.2 3,396 ± 539
18.5–24.9 905 (66.2) 34.6 ± 12.9 5.5 ± 2.6 3,620 ± 506
25.0–29.9 299 (21.9) 36.3 ± 12.0 5.6 ± 2.3 3,638 ± 547
≥ 30.0 105 (7.7) 39.3 ± 14.4 6.1 ± 2.7 3,770 ± 542
Smoking during the pregnancy
Nonsmoker 1,052 (75.1) 35.7 ± 13.3 5.6 ± 2.6 3,661 ± 514
Quit smoking 131 (9.4) 33.9 ± 11.6 5.8 ± 2.2 3,700 ± 592
1–9 cigarettes/day 109 (7.8) 35.5 ± 12.7 5.8 ± 2.6 3,434 ± 469
≥ 10 cigarettes/day 108 (7.7) 32.5 ± 11.9 4.9 ± 1.9 3,384 ± 560
Sex
Female 690 (49.3) 35.3 ± 13.0 5.5 ± 2.4 3,582 ± 538
Male 710 (50.7) 35.2 ± 12.9 5.6 ± 2.7 3,668 ± 518
aMissing data: maternal age (1), socio-occupational status (4), prepregnancy BMI (33), birth weight (12).
Table 2. Concentrations of PFOS and PFOA in the
maternal and cord blood samples and birth out-
comes of study subjects.
No. Value
1st maternal blood levels (ng/mL)a
PFOS 1,399 35.3  ± 13.0
PFOA 1,399 5.6 ± 2.5
2nd maternal blood levels (ng/mL)
PFOS 200 29.9  ± 11.0
PFOA 200 4.5 ± 1.9
Umbilical cord blood levels (ng/mL)
PFOS 50 11.0  ± 4.7
PFOA 50 3.7 ± 3.4
Birth weight (g)  1,388 3623 ± 238
Low birth weight (< 2,500 g) 24 (1.7)
Gestational age (days) 1,399 280.4 ± 11.0
Preterm birth (< 259 days) 53 (3.8)
Post-term (≥ 294 days) 139 (9.9)
Values are mean ± SD or no. (%). 
aA total of 1,399 first maternal blood samples were ana-
lyzed because one blood sample was missing.from 15 frozen whole blood samples (12 ﬁrst
maternal blood samples, 1 second blood sam-
ple, and 2 cord blood samples). These were
multiplied by a factor of two to make them
comparable to measurements made on plasma
(Ehresman et al. 2007).
Statistical analysis. We used analyses of
variance and linear regression to assess the
associations between birth weight and length
of gestation and maternal plasma PFOS and
PFOA levels. We used logistic regression to
estimate odds ratio (OR) and 95% conﬁdence
interval (CI) for low birth weight, SGA, and
preterm birth. The PFOS and PFOA levels
were entered into the analyses as both contin-
uous and categorical variables (< 25th, 25th–
< 50th, 50th– < 75th, ≥ 75th). Plasma levels
below the 25th percentile were used as the
reference group when using categorical vari-
ables. Both log-transformed and untrans-
formed blood PFC concentrations were tested
in the statistical models, and the ﬁndings were
similar. For this article, we used only the
results of untransformed concentrations. We
also conducted regression diagnostics for
influential points using Cook’s distance, but
no substantial changes in estimates were
observed before or after the inﬂuential points
were excluded, and our results are therefore
all based on the whole data set.
We adjusted for risk factors that could
influence fetal growth or length of gestation
at birth. These factors included maternal age,
parity, socio-occupational status, prepreg-
nancy BMI, smoking during pregnancy,
infant sex, and gestational week at blood
drawing. For birth weight, we also adjusted
for gestational age at birth, measured in days
and entered as linear and quadratic terms into
the model to capture the reduced weight gain
during the last weeks. All covariates but gesta-
tional age at birth and gestational week at
blood drawing were introduced into models
as indicator variables. Stratified analyses by
parity, prepregnancy BMI, term of birth
(preterm, term, and post-term) and sex were
also performed to evaluate the consistency of
the associations across strata.
Results
Demographic and other characteristics of the
study participants are presented in Table 1.
Almost half of the women were having their
first babies, and the average age at delivery
was about 30 years. Almost 25% smoked in
early pregnancy, but one-third of these
reported quitting smoking during pregnancy.
Almost 30% had a prepregnancy BMI of
≥ 25 kg/m2. The mean birth weight was
3,623 g, and the incidence of LBW was
1.7%; the mean gestational age at birth was
280 days, and the incidence of preterm birth
and post-term birth was 3.8% and 9.9%,
respectively (Table 2). On average, birth
weight increased with maternal age, parity,
and prepregnancy BMI and was lower among
smokers (Table 1).
All the first maternal blood samples had
PFOS levels above the LLOQ, and only one
had a PFOA level below the LLOQ. The
plasma concentrations varied substantially,
with a range of 6.4–106.7 ng/mL for PFOS
values, and less than the LLOQ to 41.5 ng/mL
for PFOA values. PFOS and PFOA levels
decreased with increasing parity. The mean
concentration of PFOA was highest in the age
group of < 25 years (6.2 ng/mL), and lowest in
the age group of ≥ 35 years (5.1 ng/mL), but
after adjustment for parity the difference was
reduced to 0.4 ng/mL. High levels were also
observed in overweight and obese women
(Table 1).
Figure 1 shows scatterplots for the first
maternal blood PFOS and PFOA levels and
birth weight. The adjusted association
between PFOS levels and birth weight was
close to null, but birth weight was inversely
associated with plasma levels of PFOA in the
ﬁrst blood sample (Table 3). The unadjusted
regression coefficient was –20.52 (95% CI,
–31.49 to –9.56) (Figure 1), but adjustment
for potential confounders reduced the esti-
mate to –10.63 (95% CI, –20.79 to –0.47)
(Table 3). Parity was the covariate that most
markedly changed the regression coefficient.
PFOA levels were correlated with PFOS levels
(r = 0.62), and after adjustment for PFOS
levels in the first maternal blood, the regres-
sion coefficient of PFOA became slightly
stronger (β = –14.85; 95% CI, –27.67 to
–2.02). Analyses stratified by term of birth
(preterm, term, post-term) revealed that the
effects of PFOA on birth weight were more
pronounced in preterm and post-term babies
(Table 3), but did not differ markedly by sex
or parity. PFOA levels were significantly
inversely associated with birth weight only
among normal-weight women.
Infants born to mothers with PFOA levels
in the three highest quartiles had an adjusted
average birth weight of 96, 98, and 105 g
lower than infants born to mothers in the
lowest quartile, respectively (Table 4). No sta-
tistically significant association was observed
between either PFOS or PFOA and length of
gestation (Table 4). Elevated risk estimates for
preterm birth were observed at all levels of
PFOS and PFOA, but only the ORs for the
Perfluorinated chemicals and fetal growth
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Table 3. Adjusted regression coefﬁcients [β (95% CI)] between PFOS and PFOA (ng/mL) in ﬁrst maternal
blood during pregnancy and birth weight (g).
Strata PFOS PFOA
Alla –0.46 (–2.34 to 1.41) –10.63 (–20.79 to –0.47)
Term of birtha
Preterm –2.27 (–20.94 to 16.40) –43.38 (–141.11 to 54.34)
Term 0.29 (–1.72 to 2.27) –8.73 (–19.53 to 2.06)
Post-term –4.82 (–11.10 to 1.46) –24.49 (–58.04 to 9.06)
Parityb
Nulliparous –1.17 (–4.40 to 2.06) –10.94 (–24.00 to 2.13)
Multiparous –1.23 (–3.82 to 1.35) –14.84 (–30.95 to 1.28)
Sexc
Female –1.85 (–4.49 to 0.79) –11.45 (–26.76 to 3.85)
Male 1.11 (–1.56 to 3.79) –10.36 (–24.07 to 3.34)
Prepregnancy BMI (kg/m2)d
< 18.5 5.42 (–4.34 to 15.17) 26.09 (–48.06 to 100.23)
18.5–24.9  –1.45 (–3.76 to 0.85) –15.75 (–27.75 to –3.75)
25.0–29.9 0.52 (–3.96 to 4.99) –2.03 (–26.91 to 22.85)
≥ 30.0 –0.33 (–6.60 to 5.94) 1.64 (–33.11 to 36.39)
aAdjusted for gestational age, quadratic gestational age, infant sex, maternal age, socio-occupational status, parity, ciga-
rette smoking, prepregnancy BMI, gestational weeks at blood drawing. The category deﬁnitions of the covariates were
the same as shown in Table 1. bThe models did not include parity. cThe models did not include sex. dThe models did not
include prepregnancy BMI.
Figure 1. Birth weight and plasma PFOS (A) and PFOA (B) concentrations in the ﬁrst maternal blood samples. 
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PFOS (ng/mL) PFOA (ng/mL)third quartile of PFOS and the second quar-
tile of PFOA were statistically significant
(Table 5). We did not observe any statistically
signiﬁcant association between LBW or SGA
and maternal PFOS or PFOA levels (Table 5).
There was a high degree of correlation for
PFOS or PFOA levels between the ﬁrst and sec-
ond maternal blood samples (r = 0.87 for
PFOS and 0.88 for PFOA) (Figure 2), but the
average concentrations were lower in the second
blood samples. PFOS and PFOA concentra-
tions in cord and maternal blood were also cor-
related (r = 0.72 for PFOS and 0.84 for PFOA
if two outliers were not included) (Figure 3),
but cord levels were significantly lower than
maternal levels. The mean ratios between ﬁrst
maternal PFOS and PFOA and cord concen-
trations were, respectively, 3.40 and 1.83, but
decreased between second maternal and cord
concentrations to 2.96 and 1.46.
Discussion
To our knowledge, this is the ﬁrst nationwide
population-based study on birth weight and
length of gestation with prospectively collected
data on levels of perfluorinated chemicals in
maternal sera drawn early in pregnancy. We
found only maternal plasma PFOA levels to be
inversely associated with birth weight. Risk esti-
mates for preterm birth did not increase
monotonically across quartiles of PFOS or
PFOA exposure. For all four outcomes evalu-
ated, the outcome in the lowest exposure quar-
tile differed from outcomes in the upper three
quartiles, but there was no evidence of a dose–
response association above the 25th percentile.
Maternal plasma levels in the present study
(mean concentrations: PFOS, 35.3 ng/mL;
PFOA, 5.6 ng/mL) are similar to most levels
reported for U.S. populations, but much lower
than those found in ﬂuorochemical workers or
residents living near the ﬂuoropolymer produc-
tion facilities (Emmett et al. 2006a, 2006b;
Olsen et al. 2003). We found PFOS and
PFOA levels higher than those seen among
pregnant women in other countries (Inoue
et al. 2004; Karrman et al. 2007; Midasch
et al. 2007), but that may reﬂect blood draw-
ing at different gestational week, or use of dif-
ferent assay laboratory technologies.
This study has several strengths. We used
state-of-the-art laboratory facilities, rigorous
blinding, and hospital records for obtaining
data on birth weight and gestational age. We
found a high correlation between the concen-
trations of PFOS and PFOA taken over preg-
nancy time, but the levels declined over
pregnancy time, possibly related to blood vol-
ume expansion and decreased serum albumin
concentration during pregnancy (Swanson
and King 1983; Thibodeaux et al. 2003),
changes in PFC disposition and pharmaco-
kinetics during pregnancy (Frederiksen
2001), or placental transfer of PFCs to the
Fei et al.
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Table 4. Birth weight (g) and gestational age (days) by PFOS and PFOA (in quartiles) in ﬁrst maternal blood
during pregnancy.
Birth weight (g) Gestational age (days)
No. Unadjusted mean SD No. Unadjusted mean SD
PFOS (ng/mL)
6.4–26.0 347 3,640 519 349 281.0 9.7
26.1–33.3 346 3,673 539 348 280.4 10.8
33.4–43.2 346 3,590 506 349 279.6 10.8
≥ 43.3 348 3,602 552 352 280.4 11.4
PFOA (ng/mL)
< LLOQ–3.91 348 3,737 531 349 281.1 9.6
3.91–5.20 346 3,611* 539 349 280.0 11.3
5.21–6.96 349 3,595** 512 351 279.7 11.2
≥ 6.97 344 3,562** 524 349 280.8 11.7
Because of missing records (1), blood sample (1), and birth weight (12), only 1,387 observations were used in this analysis.
Due to missing records or those records with the same values at cut-off points, the numbers in each quartile are not equal. 
*Statistically signiﬁcantly different from the lowest quartile, p-value < 0.01. **Statistically signiﬁcantly different from the
lowest quartile, p-value < 0.001.
Table 5. Adjusted OR (95% CI) for preterm birth, LBW, and SGA according to PFOS and PFOA levels (in
quartiles) in the ﬁrst maternal blood during pregnancy.
Preterm birtha LBWa SGAb
No. OR (95%CI) No. OR (95%CI) No. OR (95%CI)
PFOS (ng/mL)
6.4–26.0 7 1.00 (reference) 2 1.00 (reference) 36 1.00 (reference)
26.1–33.3 14 2.30 (0.86–6.12) 5 3.39 (0.37–31.16) 26 0.73 (0.42–1.26)
33.4–43.2 21 2.83 (1.10–7.30) 9 6.00 (0.73–49.34) 25 0.68 (0.39–1.19)
≥ 43.3 11 1.43 (0.50–4.11) 8 4.82 (0.56–41.16) 34 0.98 (0.58–1.65)
Trend (p-value)c 0.79 0.13 0.88
PFOA (ng/mL)
< LLOQ–3.91 6 1.00 (reference) 2 1.00 (reference) 29 1.00 (reference)
3.91–5.20 18 2.94 (1.05–8.28) 7 4.27 (0.50–36.51) 33 1.17 (0.68–2.00)
5.21–6.96 17 2.51 (0.87–7.27) 8 3.73 (0.42–32.45) 29 1.06 (0.61–1.84)
≥ 6.97 12 1.71 (0.55–5.28) 7 2.44 (0.27–22.25) 30 0.97 (0.55–1.70)
Trend (p-value)c 0.55 0.94 0.81
aAdjusted for infant sex, maternal age, socio-occupational status, parity, prepregnancy BMI, gestational weeks at blood
drawing, and cigarette smoking during pregnancy. bAdjusted for maternal age, socio-occupational status, prepregnancy
BMI, gestational weeks at blood drawing, and cigarette smoking during pregnancy. cThe categories of PFOS or PFOA
levels were entered as continuous variables in the test for trend.
Figure 2. Plasma PFOS (A) and PFOA (B) concentrations between the ﬁrst and second maternal blood samples.
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Figure 3. Plasma (A) and PFOA (B) concentrations between the second maternal and cord blood samples.
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48 1 2 16 20 24fetus (Apelberg et al. 2007a; Inoue et al.
2004; Midasch et al. 2007; Tittlemier et al.
2004). We also found a high correlation
between maternal and cord blood concentra-
tions. In this study we used only one mea-
surement of PFOS and PFOA, and it is
unknown how well this marker reﬂects an eti-
ologically relevant dose, which may be the
average dose over the entire pregnancy dura-
tion, a concentration at a different time in
pregnancy, or the concentration in fetal
blood. These concentrations do vary with ges-
tational age, but whether this is important for
a potential fetotoxic effect is not known.
Our nationwide study has the advantageof
being selected from a well-described cohort of
> 90,000 pregnant women and their infants
(Olsen et al. 2001). Selection bias related to
PFOA and PFOS levels or birth weight is
unlikely, because participants were enrolled
early in pregnancy and had no information on
any of these variables at that time. Information
on gestational age and birth weight came from
the Danish Hospital Discharge Register and
was based on standard clinic procedures using
ultrasound based estimates and electronic
weights. We also beneﬁted from extensive data
on potential confounders. Besides the covari-
ates in our ﬁnal model, we evaluated possible
confounding by alcohol drinking, ﬁsh intake,
protein, fat, carbohydrate, and energy intake.
Data were missing on dietary covariates for
around 20% of births, but the results remained
materially the same after these adjustments.
Adjusting for parity and prepregnancy
BMI substantially changed the crude mea-
sures of association. For instance, adjustment
for only parity in the regression model led to
attenuation of the regression coefficient
between PFOA and birth weight from –20.5
to –7.2. We did find substantially higher
PFOA levels in nulliparous women than in
multiparous women, which has been shown
before in cord blood (Apelberg et al. 2007a),
perhaps related to fetal uptake during preg-
nancy and excretion during lactation.
Unlike the more lipophilic POPs, PFOS
and PFOA do not typically accumulate in the
lipid tissues because of their oil-repellent
properties (Martin et al. 2003). Because these
compounds are retained primarily in blood
and liver, PFOS and PFOA would not be
expected to be associated with BMI. Our data
did, however, demonstrate higher plasma lev-
els of PFOS and PFOA among overweight or
obese women. In a study among 3M male
employees (Olsen et al. 1998), BMI was also
slightly but not significantly higher in the
highest PFOA category. In stratiﬁed analyses,
PFOA levels were only signiﬁcantly associated
with birth weight in normal-weight women,
suggesting effect-measure modification by
prepregnancy BMI of the association between
PFOA and birth weight.
PFOS and PFOA can cross the placental
barrier, but cord concentrations are usually
lower than those observed in maternal serum
or plasma (Inoue et al. 2004; Midasch et al.
2007; Tittlemier et al. 2004). In a recent
study based on 11 plasma samples of mothers
and the 11 corresponding cord plasma sam-
ples of neonates (Midasch et al. 2007), PFOS
cord concentrations were significantly lower
than the maternal values, but 9 of 11
neonates had higher PFOA plasma level com-
pared with those of their mothers. We found
lower mean concentrations of PFOA and
PFOS in cord blood than in maternal blood,
but PFOA levels in cord blood were much
closer than PFOS to maternal values, which
may indicate that PFOA crosses the placental
barrier more easily than PFOS. If so, that may
partly explain why we observe only an inverse
association between PFOA and birth weight,
although animal studies, as well as one cord
blood study in humans (Betts 2007), indicate
an effect of both chemicals.
The association between PFOA and birth
weight may or may not have public health
importance, even if it is causal. LBW has been
associated with higher mortality and morbid-
ity that is not restricted to early years of life
(Glucksman and Hanson 2006), although this
may reﬂect underlying causes of fetal growth
impairment rather than LBW itself.
Furthermore, the observed association may
not be causal. We did not find a monotone
dose–response relation, but our results for
birth weight, risk of preterm delivery, LBW,
and SGA are consistent with a threshold
effect. Chance may play a role in some of our
ﬁndings, and it is also possible that there are
factors associated with both lowest PFOA lev-
els and high birth weight that were not taken
into account in our statistical analyses.
The incidence of LBW and preterm birth
in our study population is relatively low due to
the selection criteria used for sampling the sub-
cohort. This should be taken into considera-
tion when trying to extrapolate our results to
other populations. We used clinical recordings
of gestational age that were often ultrasound-
based. Ultrasound-based estimates are biased if
the exposure of interest reduces very early fetal
growth. This may explain to some extent the
higher incidence of preterm birth we see
among the exposed, but analysis of gestational
age by exposure category did not provide evi-
dence for such an effect, and such a bias would
not explain differences in mean birth weight.
We observed an inverse association between
PFOA levels and birth weight, although the
maternal concentrations were orders of magni-
tude lower than those at which developmental
effects have been observed in the animal toxic-
ity studies. A risk characterization of PFOA
shows average sera concentrations associated
with the lower 95% confidence limit of the
benchmark dose for 10% response levels for
various developmental outcomes were at least
29,000 ng/mL in rat (Butenhoff et al. 2004a).
The approximate maternal sera concentrations
at which a signiﬁcant reduction of fetal body
weight occurred in mice were much higher, at
175,000 ng/mL (Lau et al. 2006). Contrary to
the relatively rapid rates of elimination reported
in laboratory animals, PFOA is eliminated
slowly in humans (Kennedy et al. 2004).
Therefore, it is hard to make a comparison with
animal data, and the necessary toxicokinetic
data in humans are lacking. Still, the adverse
effect on birth weight observed at low levels of
exposure in our study combined with ubiqui-
tous PFOA contamination in human blood
may be a cause for concern.
In conclusion, our nationwide cohort
study suggests an inverse association between
maternal levels of PFOA and birth weight.
Although PFOS and PFOA have been phased
out by some manufacturers in the United
States and in some European countries, they
are still produced elsewhere, and other similar
compounds are believed to break down
to PFOS or PFOA in the environment
(Organisation for Economic Co-operation
and Development 2002; U.S. EPA 2006). If
these compounds reduce fetal growth, contin-
ued exposure will be of public health concern,
and other potential reproductive effects
should be studied.
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